Next Article in Journal
Influence of Diminished Ovarian Reserve on Early Embryo Morphokinetics during In Vitro Fertilization: A Time-Lapse Study
Next Article in Special Issue
Detection and Prevention of Medication Errors by the Network of Sentinel Pharmacies in a Southern European Region
Previous Article in Journal
Measuring the Quality of Life in Patients with Chronic Venous Disease before and Short Term after Surgical Treatment—A Comparison between Different Open Surgical Procedures
Previous Article in Special Issue
Characteristics and Cost of Unscheduled Hospitalizations in Patients Treated with New Oral Anticancer Drugs in Germany: Evidence from the Randomized AMBORA Trial
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 11
Issue 23
10.3390/jcm11237172
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Drug-Drug Interactions among Patients Hospitalized with COVID-19 in Greece

by
Marios Spanakis
1,2,*,
Petros Ioannou
3,
Sotiris Tzalis
3,
Vasiliki Papakosta
3,
Evridiki Patelarou
1,
Nikos Tzanakis
4,
Athina Patelarou
1 and
Diamantis P. Kofteridis
3
1
Department of Nursing, School of Health Sciences, Hellenic Mediterranean University, 71004 Heraklion, Greece
2
Computational Biomedicine Laboratory, Institute of Computer Science, Foundation for Research and Technology-Hellas (FORTH), 70013 Heraklion, Greece
3
Department of Internal Medicine and Infectious Diseases, University Hospital of Heraklion, 71110 Heraklion, Greece
4
Department of Respiratory Medicine, University Hospital of Heraklion, Medical School, University of Crete, 71003 Heraklion, Greece
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2022, 11(23), 7172; https://doi.org/10.3390/jcm11237172
Submission received: 13 October 2022 / Revised: 15 November 2022 / Accepted: 29 November 2022 / Published: 2 December 2022
(This article belongs to the Special Issue Prediction, Detection and Prevention of Medication Errors and Adverse Drug Reactions)
Browse Figures
Versions Notes

Abstract

:
The modulation of the pharmacological action of drugs due to drug-drug interactions (DDIs) is a critical issue in healthcare. The aim of this study was to evaluate the prevalence and the clinical significance of potential DDIs in patients admitted to the University Hospital of Heraklion in Greece with coronavirus disease 2019 (COVID-19). Cardiovascular disorders (58.4%) and diabetes (types I and II) (29.6%) were the most common comorbidities. A high occurrence of DDIs was observed, and clinically significant DDIs that may hamper response to treatment represented 40.3% of cases on admission, 21% during hospitalization, and 40.7% upon discharge. Polypharmacy and comorbidities were associated with a higher prevalence of DDIs in a statistically significant way (p < 0.05, 95% CI). Clinically significant DDIs and increased C-reactive protein values upon admission were associated with prolonged hospitalization. The results reveal that patients admitted due to COVID-19 in Greece often have an additional burden of DDIs that healthcare teams should approach and resolve.

Graphical Abstract

1. Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes the coronavirus disease (COVID-19) has infected more than 610 million people worldwide and is responsible, until today, for more than 6.5 million deaths since its outbreak in China in 2019 [1,2]. Although it is expected that the accumulation of mutations and the currently emerging SARS-CoV-2 variants will likely lead to reduced mortality rates and transform the pandemic into its endemic phase, COVID-19 is still pressing the healthcare systems [3,4,5,6]. The most frequently associated factors for severe illness and hospitalization from COVID-19 are cardiovascular diseases, obesity, dyslipidemias, diabetes, respiratory diseases, and cancer along with aging and lack of vaccination [7,8]. Generally, people with more than one underlying health condition are at increased risk for hospitalization and acute disease [9,10,11]. Hence, COVID-19 is a common underlying condition for so many different clinical cases of patients with comorbidities [12,13]. As medical teams in COVID-19 wards try to follow efficient medication protocols for optimal healthcare provision for COVID-19 hospitalized patients, they should also adjust to each patient’s needs in order to avoid clinically significant drug-drug interactions (DDIs) from co-medications that can cause complications, adverse drug reactions (ADRs), and prolong hospitalization [14].
DDIs refer to modulations of the pharmacological profile of a drug from co-administered ones. These alterations can be related to pharmacokinetic (PK) processes of absorption, distribution, metabolism, and elimination (ADME), such as modulation of metabolic enzymes (i.e., cytochrome P450, CYPs) or transporter proteins (P-glycoprotein, P-gp; organic anion transporters, OATP) and plasma proteins (i.e., albumin). DDIs can also be related to pharmacodynamic mechanisms in the site of action and/or in other tissues [15]. Clinically significant DDIs may result in ADRs and side effects that further impair patients’ health, obscuring the treatment outcome and prolonging hospitalization [16,17]. In the case of COVID-19, the scientific community gave an early warning of the risk for DDIs from the several applied protocols [14,18,19,20,21,22,23,24]. Even with the introduction of nirmatrelvir/ritonavir (PaxlovidTM), there were regulatory check lists to assist clinicians in evaluating potential DDIs and other patient factors prior to any administration [25]. In addition, for recently approved monoclonal antibodies such as casirivimab/imdevimab (REGEN-COV) and sotrovimab (Xevudy), no official DDI studies have been performed [26,27]. They are not renally eliminated or metabolized by CYP enzymes; hence, DDIs are unlikely with drugs that are substrates, inducers, or inhibitors of CYP enzymes or excreted through the kidneys. However, caution is advised, and healthcare providers should be aware of this new field of DDIs in COVID-19 if any observation should be reported, (e.g., interactions with COVID-19 vaccinations) in terms of pharmacovigilance. In a recent review, we described the risk for potential DDIs with drugs introduced for COVID-19 for patients with respiratory disorders and presented underlying pharmacological mechanisms, their significance, and possible clinical symptoms that could be recognized by healthcare teams staffing the COVID-19 wards [18].
Advancing our approaches, the aim of this work was to record and analyze the occurrence of DDIs in COVID-19 patients hospitalized over the previous months in the University Hospital of Heraklion in Greece. The study analyzes the prevalence of DDIs among the medications administered to those patients, their clinical significance, and their potential impact on hospitalization.

2. Materials and Methods

2.1. Study Design and Ethics Approval

This observational, single-center descriptive study was conducted over a 6-month period (January–June 2022) in the COVID-19 department of the University Hospital of Heraklion in Crete, Greece. The study followed the rules of the Declaration of Helsinki of 1975, as revised in 2013, and it complied with the General Data Protection Regulation (GDPR). It was approved by both the Hellenic Mediterranean University (51/4 March 2021) and the University Hospital’s ethics committee (16105/13 October 2021). The study follows guidelines (Table 1) for reporting observational studies (Strengthening the Reporting of Observational Studies in Epidemiology—STROBE) [28].
Patients who were admitted to the COVID-19 ward, had laboratory confirmation of SARS-CoV-2 infection through reverse transcription polymerase chain reaction (RT-PCR), and willingly signed the informed consent form were analyzed. All participants were adults (18–65 years old) or elders (>65 years old). Participation was based on free will. Patients who did not understand the terms of participation and consent were excluded from the study. Patients who were not hospitalized were excluded. All data were collected and analyzed anonymously, and no interventions were made regarding healthcare provision during hospitalization.
Patients’ data were collected from the hospital’s electronic medical record system and included demographics, clinical, and laboratory data, as well as medication regimens upon admission, during hospitalization, and on the day of discharge. Polypharmacy was classified as co-administration of five or more (≥5) medications. If a medication contained more than one pharmacologically active compound, they were considered different medications (i.e., ipratropium with albuterol). Medications were classified according to the Anatomical Therapeutic Chemical (ATC) classification system (Appendix A) and were presented with its second level anatomical group-therapeutic subgroup, i.e., ATC-X00.

2.2. Evaluation of DDIs

The analysis of the DDIs and their clinical significance have been previously presented [29,30]. Briefly, medication regimens were recorded and DDIs were detected using available online drug interaction checker tools (Medscape and Drugs.com; accessed on 1 April till 30 July 2022), considering the level of evidence available in the literature describing the significance, such as experts’ opinions, in silico, in vitro, in vivo data, clinical studies, reviews, the Summary of Product Characteristics (SmPC), and reports from regulatory authorities. The DDIs were characterized as pharmacokinetic (PK) or pharmacodynamic (PD) and as “Serious-Use alternative” “Use with caution-Monitor” and “Moderate-Minor” DDIs. The ATC groups that are paired in recorded DDIs were represented with circos diagrams that were generated with Circos Table Viewer v0.63-9© (http://circos.ca, accessed on September 2022) [31].

2.3. Statistical Analysis

Data are presented as numbers or percentages for continuous variables and expressed as mean values ± standard deviation (±SD). Polypharmacy and clinically significant DDIs that were recorded were evaluated as factors that prolong hospitalization stay. In this respect, a Mann—Whitney t-test was performed with 95% confidence intervals (CI) and a statistical significance of p < 0.05 using GraphPad Prism version 8.0.1 for Windows, GraphPad Software, San Diego, CA, USA, www.graphpad.com.

3. Results

3.1. Patient Demographics, Comorbidities, and Clinical Status

The study enrolled 125 patients (76 males and 49 females) who had a positive laboratory test for SARS-CoV-2 infection (RT-PCR confirmed) and signed the informed consent form. Their demographic characteristics are presented in Table 2. They were residents of urban areas (52%), their mean age was 72.5 (±14.7) years old, with a BMI of 33.1 (±9.12) and 30% of them were smokers (Table 2). From the 125 patients, 52% were fully vaccinated (3 doses of Comirnaty, Spikevax, or 2 doses of Vaxzervria with a 3rd dose of Comirnaty), 15% were partially vaccinated (1 or 2 doses of the aforementioned vaccines), and 23% had not received any vaccine. Regarding comorbidities, a mean number of four comorbidities per patient was recorded, while 8 patients had no other medical conditions. Cardiovascular disorders (58.4%), diabetes (types I and II) (29.6%), dyslipidemias (29.6%), and respiratory disorders (20%) were the most often recorded comorbidities (Figure 1A). As far as their clinical status, upon admission, patients had low saturation (60%) and partial pressure of oxygen (O2) (63.2%), as well as high C-reactive protein (CRP) values (34.4%) (Figure 1B). The full clinical dataset as recorded is available in the Supplementary Materials. Their median hospitalization duration was 7 days (mean 8.6). The mortality within the study group was 13%.

3.2. Drugs Administered to COVID-19 Patients

Patients were prescribed cardiovascular drugs (ATC-C01, C03, C07, C08, and C09), antidiabetic drugs (ATC-A10), and lipid-modifying agents (ATC-C10), along with drugs for benign prostatic hyperplasia (ATC-G04), respiratory disorders (ATC-R03), antipsychotics (ATC-N05), and antidepressants (ATC-N06). These categories were also the most prevalent upon discharge. During hospitalization, patients’ medications were revised and modified. The general approach involved the cessation of antihypertensives, antidiabetic drugs, lipid-modifying agents, and per os anticoagulants and the initiation of therapy with low molecular weight heparin (LMWH), dexamethasone, and remdesivir. In patients with respiratory infections, cephalosporins (3rd generation) were added with or without macrolide antibiotics, and less often quinolones. To provide gastrointestinal (GI) protection, esomeprazole, or other proton-pump inhibitors (PPIs) were used. Overall, 175 different medications were recorded upon admission, which were reduced to 149 during hospitalization and 144 upon discharge. Polypharmacy (≥5 medications) accounted for 55.5% upon admission, 82% during hospitalization, and 55.6% upon discharge. An average number (±interquartile range) of 6 (±4) drugs per patient were recorded upon admission, 8 (±6) during hospitalization, and 6 (±4) upon discharge. Fitting the second level of the ATC index, they were organized into 43 different ATC groups and presented in Figure 2. During hospitalization, a rise was observed in the administration of antithrombotic agents (ATC-B01), antibacterials (ATC-J01), and antivirals (ATC-J05) for systemic use; drugs for obstructive airway diseases (ATC-R03); corticosteroids for systemic use (ATC-H02); and PPIs (ATC-A02). Corticosteroids for systemic use (ATC-H02) and drugs for obstructive airway diseases (ATC-R03) were also continued upon discharge. The most often administered drugs during hospitalization were esomeprazole (89.6%), enoxaparin (80.8%), dexamethasone (51.2%), ipratropium (32.8%), ceftriaxone (26.4%), remdesivir (22.4%), budesonide (21.6%), furosemide (18.4%), methylprednisolone (16.8%), aspirin (16%), insulin (16%), and azithromycin (15.2%).

3.3. DDIs, Clinical Significance, and Related Pharmacological Mechanisms

Drug pairs related to potential DDIs were found in 67.2% of patients during admission, 92.8% during hospitalization, and 60% upon discharge. Overall, 572 cases from 226 different drug combinations were recorded as potential DDIs. There was an average value of 3 DDIs (min = 0, max = 13) during hospitalization, whereas 2 DDIs (min = 0, max = 12) were the mean recorded value during admission and discharge (Figure 3A). There was an exponential correlation (Rc2 = 0.902) between the average number of DDIs and the number of medications administered (Figure 3B). During hospitalization, patients were exposed to a higher number of DDIs than during admission or discharge (Figure 3C).
Clinically significant DDIs such as “Serious-Use alternative” and “Use with caution-Monitor) represented 40.3% of cases at admission, 21% during hospitalization, and 40.2% upon discharge. “Moderate-Minor” DDIs were 59.8% upon admission, 77.6% during hospitalization, and 59.8% upon discharge. The analysis of DDIs revealed that 32% of them were based on PK mechanisms and the rest, 68%, on PD ones (Figure 3D). For PK-DDIs, 7% of them were recognized as “Serious-Use alternative” and 43% as “Use with caution-Monitor” and for PD-DDIs, 4% were recognized as “Serious-Use alternative” and 40% as “Use with caution-Monitor” (Figure 3E,F).
PK-DDIs were related to pharmacological mechanisms involving inhibition or induction of CYP- mediated metabolism, P-gp or OATP-mediated transport, modulation of GI absorption due to alteration of pH-dependent solubility, protein binding competition, and modulation of renal elimination that could lead to elevated concentrations for one drug and prolonged action (Table 3). PD-DDIs were related to cases that required INR monitoring, QT prolongation, imbalances in electrolytes (i.e., potassium and sodium) and blood glucose, drug-induced injuries, deterioration in renal function, and GI side effects (Table 3). Examples of drug pairs that lead to PK or PD DDIs are presented in Table 4. The overall ATC categories that were found to pair for DDIs are represented with the circos diagrams in Figure 4.
The circos diagram for PK (Figure 4A) shows an interconnection in DDIs between the use of antithrombotic agents (ATC-B01) and antibiotics (ATC-J01) (i.e., acenocoumarol and ceftriaxone) or antivirals (ATC-J05) (i.e., acenocoumarol and remdesivir) as well as with PPIs (ATC-A02) (i.e., clopidogrel-esomeprazole). The impact of PPIs on CYPs is also related to PK-DDIs with central nervous system drugs such as ATC-N06 (i.e., omeprazole and escitalopram). The modulation of CYPs and transporters can also be related to PK-DDIs such as in cases of cardiovascular medications (ATC-C01, C07, C08, and C10) (i.e., ranolazine with statins). The use of corticosteroids can impact the PK profiles of alpha-adrenoreceptor antagonists (ATC-G04) due to CYP induction. Finally, the co-administration of azithromycin (ATC-J01) can modulate the PK profile of statins (ATC-C10). Regarding circos of PD-DDIs (Figure 4B), the potential for DDIs of antithrombotic agents (ATC-B01), corticosteroids (ATC-H02), drugs for obstructive airway diseases (ATC-R03), and psychoanaleptics (ATC-N06) was observed, all of which can modulate the anticoagulation action and require INR monitoring, whereas the co-administration of agents acting on the renin–angiotensin system (ATC-C09) can cause hyperkaliemia. The use of antibacterials for systemic use (ATC-J01) can also modulate the INR values (i.e., enoxaparin and ceftaroline), whereas quinolones with corticosteroids (ATC-H02) can lead to tendon rupture and muscle damage. The co-administration of drugs for obstructive airway diseases (ATC-R03), especially β2-agonists, with cardiovascular medications such as β-blockers (ATC-C07), can result in acute bronchospasm, whereas co-administration of anticholinergics with CNS drugs (ATC-N05), such as olanzapine, can result in additive anticholinergic effects and possible hypoglycemia [32]. There are also PD-DDIs between NSAIDs and aspirin (ATC-N02), with angiotensin receptor blockers or angiotensin converting enzyme inhibitors (ATC-C09), as well as with anti-diabetic medications (ATC-A10). For CNS drugs (ATC-N03, N04, N05, and N06), there is always the risk of PD-synergism that can cause respiratory depression (i.e., carbamazepine with levomepromazine, biperiden) and additive anticholinergic effects (i.e., donepezil, haloperidol), whereas the co-administration with β-blockers can cause hypotensive effects (i.e., atenolol, zolpidem). The administration of immunosuppressants (ATC-L04) can result in DDIs either due to synergisms and the risk of serious infection (i.e., abatacept and adalimumab) or impact the CYP abundance and change drugs’ intrinsic clearance (PK-DDIs) through the liver (i.e., anakinra and alprazolam). Finally, PD-DDIs that result in QT prolongation can occur with the co-administration of antiarrhythmics (ATC-C01), antibacterials (ATC-J01), CNS medications (ATC-N05, ATC-N06), and drugs for obstructive airway diseases (ATC-R03).

3.4. Impact of Polypharmacy and DDIs on the Hospitalization Status of COVID-19 Patients

Patients over 65 had a higher number of comorbidities than adult patients below 65 (p < 0.05, 95% CI), although age and comorbidities did not seem to play any role regarding hospitalization days (p > 0.05, 95% CI). High CRP values (>10 mg/L) upon admission were associated with prolonged hospitalization days (p < 0.05, 95% CI). Polypharmacy was not associated with prolonged hospitalization (p > 0.05, 95% CI). However, patients with comorbidities had an increased number of DDIs (p < 0.05, 95% CI), and their prevalence was higher in a statistically significant way for patients in a polypharmacy state, independent of the time point (admission, hospitalization, and discharge) (p < 0.05, 95% CI). As to the clinical significance of DDIs, an apparent association between the detection of clinically significant interactions and longer hospital days was recorded. The association was mainly found in patients with CRP < 10 mg/L and clinically significant DDIs in their medication regimens upon admission (p < 0.05, 95%CI) (Figure 5).

4. Discussion

Healthcare provision for patients with SARS-CoV-2 infection has proven to be a very complicated issue that will bring transformative changes in how healthcare is provided, especially in intensive care units [33,34]. The pervasiveness of the disease creates numerous and complicated clinical scenarios for COVID-19 patients with chronic diseases and complex therapeutic schemes, which are linked with an increased risk of adverse clinical outcomes [35,36]. One of the main risk factors for ADRs is clinically significant DDIs. This work presented the results of an observational study regarding the prevalence of DDIs among 125 patients hospitalized in the COVID-19 department of the University Hospital of Heraklion in Greece. Comparably to previously published works regarding the clinical characteristics of COVID-19 patients, the patients in this study had an average number of four comorbidities: cardiovascular disease (i.e., coronary artery disease, cardiomyopathies, hypertension, etc.); diabetes (types I and II); obesity; dyslipidemias; respiratory disorders; CNS disorders; cancer (occurred most often) (Figure 1) [12,37,38,39]. Furthermore, an additional factor related to prolonged hospitalization was the increased CRP values (34.4% of the cases). CRP has also been proposed as a prognostic indicator for the assessment of disease severity in COVID-19 [40].
Potentially interacting drug pairs were found in 67.2% of patients during admission, 92.8% during hospitalization, and 60% upon discharge. Hospitalization’s high prevalence of interacting drug pairs is mostly due to the co-administration of LMWH with corticosteroids (i.e., dexamethasone), which may increase INR, a potential DDI of moderate significance. Nevertheless, the use of LMHW for anticoagulation and alleviation of inflammation mechanisms, along with dexamethasone’s effect in reducing ARDs risk, represents a prominent treatment for COVID-19 worldwide, endorsed by many medical societies’ guidelines and with a lot of evidence to support it [41,42,43,44]. Thus, careful administration of these medications should be performed while taking into consideration the underlying medical conditions, COVID-19 disease severity, as well as dexamethasone’s side effects of hyperglycemia, hypernatremia, hypertension, and potentiation of anticoagulant effects [41,45].
Pharmacological mechanisms of DDIs were related to pharmacokinetic processes in 32% of cases, and the rest (68% of cases) were related to pharmacodynamic pathways. PK-DDIs were mostly related to inhibition of CYP-mediated metabolism from perpetrator drugs, which may alter patients’ systemic drug concentrations, thus modulating its pharmacological action (Table 3 and Table 4). For example, inhibition of clopidogrel’s CYP2C19-mediated metabolism by PPIs (e.g., esomeprazole, omeprazole) may result in reduced concentrations of clopidogrel’s active metabolite and reduced antiplatelet action, whereas the co-administration of escitalopram and PPIs may lead to elevated concentrations and thus enhanced escitalopram’s pharmacological action [46,47]. PD-DDIs were mostly associated with synergistic effects of drugs that may potentiate pharmacological outcomes or increase the risk for side effects (i.e., potentiation of the anticoagulation action of antithrombotic agents or drugs that contribute to QT prolongation) [45,48].
Clinically significant DDIs of “Serious-Use alternative” or “Use with caution-Monitor” management were found in 40.3% of cases upon admission, 21% during hospitalization, and 40.7% upon discharge. The increased number of clinically significant DDIs upon admission is in line with previous observations regarding polypharmacy and the occurrence of DDIs among outpatient prescriptions in Greece [49,50]. Clinically significant DDIs at the time of admission were also associated with a longer hospital stay (p < 0.05, 95% CI). In addition, they were mostly related to PK-DDIs since the “Serious-Use alternative” DDIs represent 7% of PK-DDIs versus 4% of PD-DDIs. This is also attributed to the fact that the evaluation of significance in cases of PK-DDIs is more feasible compared to PD-DDIs since they have specific endpoints and obvious mechanisms, whereas PD-DDIs have varied outcomes, more complicated mechanisms, and clinical effects [48]. On the other hand, a reduction in the clinical significance of DDIs during hospitalization was observed compared to admission. This can be attributed to the fact that specialized and multidisciplinary healthcare teams in medical wards have additional clinical information such as laboratory values and a full medication list, which allows them to be more compliant with evidence-based clinical guidelines and proceed to a better risk/benefit analysis with fewer medication errors [29,51,52,53].
The occurrence of DDIs was higher for COVID-19 patients in a polypharmacy state (≥5 drugs). Polypharmacy is a documented risk factor for adverse drug reactions from clinically significant DDIs, especially in clinically ill patients [29,30,54]. Regarding COVID-19, polypharmacy and comorbidities have been described as risk factors for clinically significant DDIs early in the first wave, with the main concern being drug combinations that increase the risk for QT prolongation [14,35,55]. Previous studies have shown an increased prevalence of DDIs in COVD-19 patients undergoing treatment with lopinavir or ritonavir, and recognized risk factors include polypharmacy, age over 65, respiratory or CNS disorders, and dyslipidemias [56]. In our work, lopinavir and ritonavir were not administered according to the medical protocols that were followed. However, risk factors such as polypharmacy and comorbidities were also correlated with the high prevalence of DDIs (Figure 5). In addition, QT prolongation (Table 3) was the second most common potential outcome among the PD-DDIs due to the co-administration of antiarrhythmics (ATC-C01), antibacterials (ATC-J01), and especially azithromycin, CNS medications (ATC-N05, ATC-N06), and drugs for obstructive airway diseases (ATC-R03). In other studies, hypoglycemia and QT prolongation have been reported to be the most common predicted outcomes of DDIs, with risk factors being polypharmacy and comorbidities, whereas a correlation between the average number of drugs and the number of medications was observed [57]. In our study, the risk for hypoglycemia was less frequent (Table 3), but again, we observed an association between the number of drugs and DDIs (Figure 5). Overall, treating physicians in COVID-19 wards should be aware of potential PK-DDIs when antithrombotic agents (ATC-B01), antibiotics (ATC-J01), and antivirals (ATC-J05), as well as PPIs (ATC-A02), are co-administered along with cardiovascular medications (ATC-C). Regarding PD-DDIs, they should consider potential DDIs if arrhythmias occur due to the co-administration of drugs that prolong the QT interval. In addition, if INR values are modulated, it can be related to the co-administration of antithrombotic agents (ATC-B01), antibacterial agents (ATC-J01), corticosteroids (ATC-H02), drugs for obstructive airway diseases (ATC-R03), and psychoanaleptics (ATC-N06). They should also be aware of potential synergistic PD-DDIs that can be associated with the co-administration of CNS drugs (ATC-N) (Table 4 and Figure 4) [14,21,35,55,58,59].
Until today, several risk score calculators have been developed to aid clinical decisions for COVID-19 patients [60,61]. Usually, these approaches take into consideration the clinical characteristics and risk factors that, until today, have been recognized for COVID-19. These patients are usually under polypharmacy conditions and thus at risk for ADRs from DDIs. This is a factor that should always be considered and incorporated into risk score calculators. Previous research has demonstrated that COVID-19 patients have a high prevalence of DDIs, especially those on polypharmacy [57,62]. This was evident also in this study, which estimated an exponential correlation between the number of medications and the average number of DDIs. On the subject of the apparent association between clinically significant DDIs and prolonged hospitalization, the current study cannot provide a causality conclusion as to whether DDIs actually prolong hospitalization or occur due to complex treatment regimens in prolonged hospitalized patients. Hence, prospective studies are needed to further clarify the possible causality of the observation for COVID-19 patients [16,17,63]. On the other hand, the reduction in the clinical significance of DDIs reveals that specialized medical teams can reduce the burden of DDIs among hospitalized patients and improve the healthcare provided. Overall, clinical signs, such as excessive or reduced drug action, modulation of INR, QT prolongation, and Torsades de Pointes (TdP), changes in electrolytes (K+, Na+), hyper/hypoglycemia, sedation, respiratory depression, and muscle, kidney, or liver dysfunctions, should be approached from a DDIs point of view for hospitalized COVID-19 patients, similar to those described in other works and in this study.
Limitations of the study that can be mentioned are the relatively condensed sample size and that it took place in one hospital. However, the analysis of the data revealed a good correlation between the clinical characteristics of this cohort and the occurrence of DDIs compared with the literature for COVID-19 [64].

5. Conclusions

The current study examined the prevalence of DDIs among patients in the COVID-19 department of the University Hospital of Heraklion in Greece. Clinically significant DDIs related to comorbidities and polypharmacy that can hinder treatment response and complicate hospitalization were recorded mostly upon admission and to a lesser extent during hospitalization. COVID-19, even as an endemic disease, will remain a permanent burden that challenges healthcare provision. Clinicians should be aware of and follow stepwise approaches to control inflammation and prevent acute respiratory distress syndrome (ARDS), as well as to avoid or minimize clinically significant DDIs and relative ADRs that may complicate hospitalization and treatment outcomes.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11237172/s1, Figure S1: Clinical values of COVID-19 hospitalized patients; Table S1: ST 1 Drug combinations that may lead in pharmacokinetic DDIs as they recorded in the current study. Table S2: Drug combinations that may lead in pharmacodynamic DDIs as they recorded in the current study.

Author Contributions

Conceptualization and visualization M.S.; methodology, P.I.; formal analysis, investigation, data curation, S.T. and V.P.; supervision, E.P. and A.P.; resources, N.T. and D.P.K.; project administration A.P.; writing—original draft preparation, M.S.; writing—review and editing M.S., P.I. and A.P. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of Hellenic Mediterranean University (51/4 March 2021) and the University Hospital of Heraklion (16105/13 October 2021). The study was conducted as part of a research process. Data recording and analysis were done without motivation, were not influenced by any other factors (economic, social, or political), and were conducted with absolute respect for the bioethical, physical, and mental condition of each participant.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

During the data collection and analysis, all procedures were followed to ensure the confidentiality of the participants in accordance with EU directives and the General Data Protection Regulation (GDPR). The data presented in the study are available for use upon reasonable request/permission from the corresponding author. The data are not publicly available due to privacy statements and ethical reasons that were included in the informed consent form signed by the participants.

Acknowledgments

We acknowledge the patients who agreed to participate in the study.

Conflicts of Interest

The authors declare no conflict of interest.

Appendix A

Drugs were classified and presented in figures and tables according to the Anatomical Therapeutic Chemical (ATC) classification system. The table in the appendix shows the pharmacological subgroups of drugs that were classified into the respective ATC groups.
Table
Table A1. ATC classification (2nd level, anatomical group-therapeutic subgroup) of drugs in the study.
Table A1. ATC classification (2nd level, anatomical group-therapeutic subgroup) of drugs in the study.
ATC-CodesDrug CategoryPharmacological Subgroup
A02Drugs for acid-related disordersProton pump inhibitors
A10Drugs used in diabetesBiguanides; dipeptidyl peptidase 4 (DPP-4) inhibitors; sodium-glucose co-transporter 2 (SGLT2) inhibitors
A11VitaminsVitamin B-complex
A12Mineral supplementsCalcium, combinations with vitamin D; potassium; magnesium
B01Antithrombotic agentsVitamin-K antagonists; heparin group; direct oral anticoagulants
B03Antianemic preparationsFerrous supplements
C01Cardiac therapyCardiac glycosides; antiarrhythmics; Vasodilators
C02AntihypertensivesImidazoline receptor agonists
C03DiureticsThiazides; sulfonamides; aldosterone antagonists
C07β-blockersselective β-blockers, α-and β-blockers
C08Ca2+ channel blockers (CCBs)CCBs with vascular effects; CCBs with direct cardiac effects
C09Agents acting on the renin–angiotensin systemACE inhibitors; ARBs
C10Lipid modifying agentsHMG CoA reductase inhibitors (statins)
G03Sex hormones and modulators of the genital systemProgestogens and estrogens
G04UrologicalsDrugs used in benign prostatic hypertrophy
H02Corticosteroids for systemic useGlucocorticoids
H03Thyroid therapyThyroid hormones
J01Antibacterials for systemic usePenicillins; macrolides; quinolones
J02Antimycotics for systemic useImidazole and triazole derivatives
J05Antivirals for systemic useDirect acting antiviral drugs (remdesivir)
L01Antineoplastic agentsProtein kinase inhibitors
L02Endocrine therapyGonadotropin-releasing hormone analogs
L04ImmunosuppressantsInterleukin inhibitors; antimetabolites
M04Antigout preparationsUric acid inhibitors
N02AnalgesicsAnalgesics and antipyretics
N03AntiepilepticsCarboxamide (carbamazepine) and fatty acid (valproic acid) derivatives
N04Anti-Parkinson drugsDopaminergic agents
N05PsycholepticsAntipsychotics, anxiolytics, and sedatives
N06PsychoanalepticsAntidepressants
R03Drugs for obstructive airway diseasesβ-2-receptor agonists; glucocorticoids

References

  1. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497–506. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020, 395, 507–513. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Biancolella, M.; Colona, V.L.; Mehrian-Shai, R.; Watt, J.L.; Luzzatto, L.; Novelli, G.; Reichardt, J.K.V. COVID-19 2022 update: Transition of the pandemic to the endemic phase. Hum. Genom. 2022, 16, 1–12. [Google Scholar] [CrossRef] [PubMed]
  4. Taylor, C.A.; Whitaker, M.; Anglin, O.; Milucky, J.; Patel, K.; Pham, H.; Chai, S.J.; Alden, N.B.; Yousey-Hindes, K.; Anderson, E.J.; et al. COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status—COVID-NET, 14 States, July 2021–January 2022. MMWR. Morb. Mortal. Wkly. Rep. 2022, 71, 466–473. [Google Scholar] [CrossRef] [PubMed]
  5. Jassat, W.; Abdool Karim, S.S.; Mudara, C.; Welch, R.; Ozougwu, L.; Groome, M.J.; Govender, N.; von Gottberg, A.; Wolter, N.; Wolmarans, M.; et al. Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: A retrospective observational study. Lancet Glob. Health 2022, 10, e961–e969. [Google Scholar] [CrossRef]
  6. Nyberg, T.; Ferguson, N.M.; Nash, S.G.; Webster, H.H.; Flaxman, S.; Andrews, N.; Hinsley, W.; Bernal, J.L.; Kall, M.; Bhatt, S.; et al. Comparative Analysis of the Risks of Hospitalisation and Death Associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) Variants in England. SSRN Electron. J. 2022, 399, 1303–1312. [Google Scholar] [CrossRef]
  7. Zhou, Y.; Yang, Q.; Chi, J.; Dong, B.; Lv, W.; Shen, L.; Wang, Y. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. Int. J. Infect. Dis. 2020, 99, 47–56. [Google Scholar] [CrossRef]
  8. Du, P.; Li, D.; Wang, A.; Shen, S.; Ma, Z.; Li, X. A Systematic Review and Meta-Analysis of Risk Factors Associated with Severity and Death in COVID-19 Patients. Can. J. Infect. Dis. Med. Microbiol. 2021, 2021, 6660930. [Google Scholar] [CrossRef]
  9. Vahey, G.M.; McDonald, E.; Marshall, K.; Martin, S.W.; Chun, H.; Herlihy, R.; Tate, J.E.; Kawasaki, B.; Midgley, C.M.; Alden, N.; et al. Risk factors for hospitalization among persons with COVID-19—Colorado. PLoS ONE 2021, 16, e0256917. [Google Scholar] [CrossRef]
  10. Molani, S.; Hernandez, P.V.; Roper, R.T.; Duvvuri, V.R.; Baumgartner, A.M.; Goldman, J.D.; Ertekin-Taner, N.; Funk, C.C.; Price, N.D.; Rappaport, N.; et al. Risk factors for severe COVID-19 differ by age for hospitalized adults. Sci. Rep. 2022, 12, 6568. [Google Scholar] [CrossRef]
  11. Hergens, M.P.; Bell, M.; Haglund, P.; Sundström, J.; Lampa, E.; Nederby-Öhd, J.; Östlund, M.R.; Cars, T. Risk factors for COVID-19-related death, hospitalization and intensive care: A population-wide study of all inhabitants in Stockholm. Eur. J. Epidemiol. 2022, 37, 157–165. [Google Scholar] [CrossRef] [PubMed]
  12. Ng, W.H.; Tipih, T.; Makoah, N.A.; Vermeulen, J.G.; Goedhals, D.; Sempa, J.B.; Burt, F.J.; Taylor, A.; Mahalingam, S. Comorbidities in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis. MBio 2021, 12, e03647-20. [Google Scholar] [CrossRef] [PubMed]
  13. Bajgain, K.T.; Badal, S.; Bajgain, B.B.; Santana, M.J. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature. Am. J. Infect. Control 2021, 49, 238–246. [Google Scholar] [CrossRef]
  14. Preskorn, S.H.; Quadri, S. Why Are Patients With COVID-19 at Risk for Drug-Drug Interactions? J. Psychiatr. Pract. 2020, 26, 485–492. [Google Scholar] [CrossRef] [PubMed]
  15. Aronson, J.K. Classifying drug interactions. Br. J. Clin. Pharmacol. 2004, 58, 343–344. [Google Scholar] [CrossRef] [Green Version]
  16. Kohler, G.I.; Bode-Boger, S.M.; Busse, R.; Hoopmann, M.; Welte, T.; Boger, R.H. Drug-drug interactions in medical patients: Effects of in-hospital treatment and relation to multiple drug use. Int. J. Clin. Pharmacol. Ther. 2000, 38, 504–513. [Google Scholar] [CrossRef]
  17. Dechanont, S.; Maphanta, S.; Butthum, B.; Kongkaew, C. Hospital admissions/visits associated with drug-drug interactions: A systematic review and meta-analysis. Pharmacoepidemiol. Drug Saf. 2014, 23, 489–497. [Google Scholar] [CrossRef]
  18. Spanakis, M.; Patelarou, A.; Patelarou, E.; Tzanakis, N. Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments. Int. J. Environ. Res. Public Health 2021, 18, 11711. [Google Scholar] [CrossRef]
  19. Conti, V.; Sellitto, C.; Torsiello, M.; Manzo, V.; De Bellis, E.; Stefanelli, B.; Bertini, N.; Costantino, M.; Maci, C.; Raschi, E.; et al. Identification of Drug Interaction Adverse Events in Patients With COVID-19: A Systematic Review. JAMA Netw. Open 2022, 5, e227970. [Google Scholar] [CrossRef]
  20. Rezaee, H.; Pourkarim, F.; Pourtaghi-Anvarian, S.; Entezari-Maleki, T.; Asvadi-Kermani, T.; Nouri-Vaskeh, M. Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview. Pharmacol. Res. Perspect. 2021, 9, e00705. [Google Scholar] [CrossRef]
  21. Baburaj, G.; Thomas, L.; Rao, M. Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies. Arch. Med. Res. 2021, 52, 261–269. [Google Scholar] [CrossRef] [PubMed]
  22. Mohebbi, N.; Talebi, A.; Moghadamnia, M.; Taloki, Z.N.; Shakiba, A. Drug interactions of psychiatric and COVID-19 medications. Basic Clin. Neurosci. 2020, 11, 185–200. [Google Scholar] [CrossRef] [PubMed]
  23. Sahin, S.; Karsidag, S.; Cinar, N.; Ates, M.F.; Demir, S.; Eren, F.; Neyal, A.; Kisabay Ak, A.; Bora Tokcaer, A.; Erkoc Ataoglu, E.; et al. The Impact of the COVID-19 Lockdown on the Quality of Life in Chronic Neurological Diseases: The Results of a COVQoL-CND Study. Eur. Neurol. 2021, 84, 450–459. [Google Scholar] [CrossRef] [PubMed]
  24. Jeong, E.; Nelson, S.D.; Su, Y.; Malin, B.; Li, L.; Chen, Y. Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system. Front. Pharmacol. 2022, 13, 2853. [Google Scholar] [CrossRef]
  25. Larkin, H.D. Paxlovid Drug Interaction Screening Checklist Updated. JAMA 2022, 328, 1290. [Google Scholar] [CrossRef]
  26. Hoffmann-La Roche Limited. Casirivimab and Imdevimab for Injection-Product Monograph; Hoffmann-La Roche Limited: Mississauga, ON, Canada, 2021. [Google Scholar]
  27. GlaxoSmithKline. Xevudy-Annex i Summary of Product Characteristics; GlaxoSmithKline Trading Services Limited: Dublin, Ireland, 2022. [Google Scholar]
  28. Vandenbroucke, J.P.; Von Elm, E.; Altman, D.G.; Gøtzsche, P.C.; Mulrow, C.D.; Pocock, S.J.; Poole, C.; Schlesselman, J.J.; Egger, M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. Epidemiology 2007, 18, 805–835. [Google Scholar] [CrossRef] [Green Version]
  29. Spanakis, M.; Melissourgaki, M.; Lazopoulos, G.; Patelarou, A.E.; Patelarou, E. Prevalence and clinical significance of drug–drug and drug–dietary supplement interactions among patients admitted for cardiothoracic surgery in greece. Pharmaceutics 2021, 13, 239. [Google Scholar] [CrossRef]
  30. Spanakis, M.; Roubedaki, M.; Tzanakis, I.; Zografakis-Sfakianakis, M.; Patelarou, E.; Patelarou, A. Impact of adverse drug reactions in patients with end stage renal disease in Greece. Int. J. Environ. Res. Public Health 2020, 17, 9101. [Google Scholar] [CrossRef]
  31. Krzywinski, M.; Schein, J.; Birol, I.; Connors, J.; Gascoyne, R.; Horsman, D.; Jones, S.J.; Marra, M.A. Circos: An information aesthetic for comparative genomics. Genome Res. 2009, 19, 1639–1645. [Google Scholar] [CrossRef] [Green Version]
  32. Ajimura, C.M.; Jagan, N.; Morrow, L.E.; Malesker, M.A. Drug Interactions with Oral Inhaled Medications. J. Pharm. Technol. 2018, 34, 273. [Google Scholar] [CrossRef]
  33. Robinson, P.C.; Liew, D.F.L.; Tanner, H.L.; Grainger, J.R.; Dwek, R.A.; Reisler, R.B.; Steinman, L.; Feldmann, M.; Ho, L.P.; Hussell, T.; et al. COVID-19 therapeutics: Challenges and directions for the future. Proc. Natl. Acad. Sci. USA 2022, 119, e2119893119. [Google Scholar] [CrossRef] [PubMed]
  34. Arabi, Y.M.; Azoulay, E.; Al-Dorzi, H.M.; Phua, J.; Salluh, J.; Binnie, A.; Hodgson, C.; Angus, D.C.; Cecconi, M.; Du, B.; et al. How the COVID-19 pandemic will change the future of critical care. Intensive Care Med. 2021, 47, 282–291. [Google Scholar] [CrossRef] [PubMed]
  35. Iloanusi, S.; Mgbere, O.; Essien, E.J. Polypharmacy among COVID-19 patients: A systematic review. J. Am. Pharm. Assoc. 2021, 61, e14–e25. [Google Scholar] [CrossRef] [PubMed]
  36. Crescioli, G.; Brilli, V.; Lanzi, C.; Burgalassi, A.; Ieri, A.; Bonaiuti, R.; Romano, E.; Innocenti, R.; Mannaioni, G.; Vannacci, A.; et al. Adverse drug reactions in SARS-CoV-2 hospitalised patients: A case-series with a focus on drug–drug interactions. Intern. Emerg. Med. 2021, 16, 697–710. [Google Scholar] [CrossRef] [PubMed]
  37. Gold, M.S.; Sehayek, D.; Gabrielli, S.; Zhang, X.; McCusker, C.; Ben-Shoshan, M. COVID-19 and comorbidities: A systematic review and meta-analysis. Postgrad. Med. 2020, 132, 749–755. [Google Scholar] [CrossRef]
  38. Richardson, S.; Hirsch, J.S.; Narasimhan, M.; Crawford, J.M.; McGinn, T.; Davidson, K.W.; Barnaby, D.P.; Becker, L.B.; Chelico, J.D.; Cohen, S.L.; et al. Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area. JAMA—J. Am. Med. Assoc. 2020, 323, 2052–2059. [Google Scholar] [CrossRef]
  39. Zaman, M.; Khan, W.A.; Rajaram, S.S. Comorbidities and COVID-19. In COVID-19 by Cases: A Pandemic Review; British Medical Journal Publishing Group: London, UK, 2021; Volume 377, pp. 283–294. ISBN 9781685072629. [Google Scholar]
  40. Sharifpour, M.; Rangaraju, S.; Liu, M.; Alabyad, D.; Nahab, F.B.; Creel-Bulos, C.M.; Jabaley, C.S. C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19. PLoS ONE 2020, 15, e0242400. [Google Scholar] [CrossRef]
  41. Braz-de-Melo, H.A.; Faria, S.S.; Pasquarelli-do-Nascimento, G.; Santos, I.D.O.; Kobinger, G.P.; Magalhães, K.G. The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19. Front. Med. 2021, 8, 615333. [Google Scholar] [CrossRef]
  42. NIH. COVID-19 Treatment Guidelines 2. Available online: https://www.covid19treatmentguidelines.nih.gov/ (accessed on 3 August 2022).
  43. National Public Health Organization EOODY COVID-19 Guidelines. Available online: https://eody.gov.gr/wp-content/uploads/2022/02/covid_19_algorithmos-nosileuomenon_20220217.pdf (accessed on 11 September 2022).
  44. Cattaneo, D.; Pasina, L.; Maggioni, A.P.; Oreni, L.; Conti, F.; Pezzati, L.; Casalini, G.; Bonazzetti, C.; Morena, V.; Ridolfo, A.; et al. Drug–Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients. Drugs Aging 2021, 38, 341–346. [Google Scholar] [CrossRef]
  45. Khiali, S.; Entezari-Maleki, T. Anticoagulation in COVID-19: DDI Perspective. Clin. Appl. Thromb. 2020, 26, 1076029620959457. [Google Scholar] [CrossRef]
  46. Laine, L.; Hennekens, C. Proton pump inhibitor and clopidogrel interaction: Fact or fiction. Am. J. Gastroenterol. 2010, 105, 34–41. [Google Scholar] [CrossRef] [PubMed]
  47. Gjestad, C.; Westin, A.A.; Skogvoll, E.; Spigset, O. Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline. Ther. Drug Monit. 2015, 37, 90–97. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Wiśniowska, B.; Tylutki, Z.; Wyszogrodzka, G.; Polak, S. Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect—comprehensive overview of clinical trials. BMC Pharmacol. Toxicol. 2016, 17, 12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  49. Chatsisvili, A.; Sapounidis, I.; Pavlidou, G.; Zoumpouridou, E.; Karakousis, V.-A.A.; Spanakis, M.; Teperikidis, L.; Niopas, I. Potential drug–drug interactions in prescriptions dispensed in community pharmacies in Greece. Pharm. World Sci. 2010, 32, 187–193. [Google Scholar] [CrossRef] [PubMed]
  50. Charalampopoulou, E.; Kontogiorgis, C.; Nena, E.; Constantinides, T.; Kolios, G. The complex phenomenon of polypharmacy in older age people of Greece: Data from the new era of e-prescribing. Drugs Ther. Perspect. 2017, 33, 580–584. [Google Scholar] [CrossRef]
  51. Andersson, M.L.; Böttiger, Y.; Kockum, H.; Eiermann, B. High Prevalence of Drug–Drug Interactions in Primary Health Care is Caused by Prescriptions from other Healthcare Units. Basic Clin. Pharmacol. Toxicol. 2018, 122, 512–516. [Google Scholar] [CrossRef] [Green Version]
  52. Manias, E.; Kusljic, S.; Wu, A. Interventions to reduce medication errors in adult medical and surgical settings: A systematic review. Ther. Adv. Drug Saf. 2020, 11. [Google Scholar] [CrossRef]
  53. Perez, M.; Masse, M.; Deldicque, A.; Beuscart, J.B.; De Groote, P.; Desbordes, J.; Fry, S.; Musy, E.; Odou, P.; Puisieux, F.; et al. Analysis of clinical pharmacist interventions in the COVID-19 units of a French university hospital. Eur. J. Hosp. Pharm. 2021, 29, e30–e35. [Google Scholar] [CrossRef]
  54. Guthrie, B.; Makubate, B.; Hernandez-Santiago, V.; Dreischulte, T. The rising tide of polypharmacy and drug-drug interactions: Population database analysis 1995-2010. BMC Med. 2015, 13, 74. [Google Scholar] [CrossRef] [Green Version]
  55. Cantudo-Cuenca, M.D.; Gutiérrez-Pizarraya, A.; Pinilla-Fernández, A.; Contreras-Macías, E.; Fernández-Fuertes, M.; Lao-Domínguez, F.A.; Rincón, P.; Pineda, J.A.; Macías, J.; Morillo-Verdugo, R. Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. Sci. Rep. 2021, 11, 1–8. [Google Scholar] [CrossRef]
  56. Brandariz-Nuñez, D.; Correas-Sanahuja, M.; Guarc, E.; Picón, R.; García, B.; Gil, R. Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir. Med. Clin. 2020, 155, 281–287. [Google Scholar] [CrossRef] [PubMed]
  57. Manjhi, P.K.; Kumar, R.; Priya, A.; Rab, I. Drug-Drug Interactions in Patients with COVID-19: A Retrospective Study at a Tertiary Care Hospital in Eastern India. Maedica 2021, 16, 163–169. [Google Scholar] [CrossRef] [PubMed]
  58. Armahizer, M.J.; Seybert, A.L.; Smithburger, P.L.; Kane-Gill, S.L. Drug-drug interactions contributing to QT prolongation in cardiac intensive care units. J. Crit. Care 2013, 28, 243–249. [Google Scholar] [CrossRef] [PubMed]
  59. Vieweg, W.V.R. New Generation Antipsychotic Drugs and QTc Interval Prolongation. Prim. Care Companion J. Clin. Psychiatry 2003, 05, 205–215. [Google Scholar] [CrossRef] [Green Version]
  60. Clift, A.K.; Coupland, C.A.C.; Keogh, R.H.; Diaz-Ordaz, K.; Williamson, E.; Harrison, E.M.; Hayward, A.; Hemingway, H.; Horby, P.; Mehta, N.; et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: National derivation and validation cohort study. BMJ 2020, 371, m3731. [Google Scholar] [CrossRef]
  61. Nafilyan, V.; Humberstone, B.; Mehta, N.; Diamond, I.; Coupland, C.; Lorenzi, L.; Pawelek, P.; Schofield, R.; Morgan, J.; Brown, P.; et al. An external validation of the QCovid risk prediction algorithm for risk of mortality from COVID-19 in adults: A national validation cohort study in England. Lancet. Digit. Health 2021, 3, e425–e433. [Google Scholar] [CrossRef]
  62. Saber-Moghaddam, N.; Hejazi, S.; Elyasi, S. Potential Drug–Drug Interactions among Hospitalized COVID-19 Patients Admitted to Medical Wards of a Referral Hospital, North-East of Iran: A Cross Sectional Study. J. Pharm. Care 2021, 9, 88–95. [Google Scholar] [CrossRef]
  63. Moura, C.; Prado, N.; Acurcio, F. Potential drug-drug interactions associated with prolonged stays in the intensive care unit: A retrospective cohort study. Clin. Drug Investig. 2011, 31, 309–316. [Google Scholar] [CrossRef]
  64. ECDC Weekly Epidemiological Update: Omicron Variant of Concern (VOC)—Week 1 (data as of 7 January 2022) EU/EEA. Available online: https://www.ecdc.europa.eu/en/news-events/weekly-epidemiological-update-omicron-variant-concern-voc-week-2-data-20-january-2022 (accessed on 15 September 2022).
Jcm 11 07172 g001 550
Figure 1. (A) Comorbidities that were recorded among the cohort of COVID-19 patients. (B) Clinical data of oxygen saturation (saturation O2), partial pressure of O2 (pO2), and C-reactive protein (CRP) for those patients. The gray dashed lines represent the normal laboratory values.
Figure 1. (A) Comorbidities that were recorded among the cohort of COVID-19 patients. (B) Clinical data of oxygen saturation (saturation O2), partial pressure of O2 (pO2), and C-reactive protein (CRP) for those patients. The gray dashed lines represent the normal laboratory values.
Jcm 11 07172 g001
Jcm 11 07172 g002 550
Figure 2. ATC drug categories that were administered to COVID-19 patients during admission (blue bars), hospitalization (red bars), and discharge (yellow bars).
Figure 2. ATC drug categories that were administered to COVID-19 patients during admission (blue bars), hospitalization (red bars), and discharge (yellow bars).
Jcm 11 07172 g002
Jcm 11 07172 g003 550
Figure 3. (A) Average drugs administered and drug-drug interactions (DDIs) per each time point. (B) Average number of DDIs over number of administered drugs. (C) Patient exposure in DDIs (%) for each time point. (D) Pharmacological mechanisms and clinical significance for (E) Pharmacokinetic (PK)-DDIs and (F) Pharmacodynamic (PD)-DDIs.
Figure 3. (A) Average drugs administered and drug-drug interactions (DDIs) per each time point. (B) Average number of DDIs over number of administered drugs. (C) Patient exposure in DDIs (%) for each time point. (D) Pharmacological mechanisms and clinical significance for (E) Pharmacokinetic (PK)-DDIs and (F) Pharmacodynamic (PD)-DDIs.
Jcm 11 07172 g003
Jcm 11 07172 g004 550
Figure 4. Circos plots displaying the interconnections between ATC categories that can lead to (A) pharmacokinetic drug-drug interactions and (B) pharmacodynamic drug-drug interactions as described in this study.
Figure 4. Circos plots displaying the interconnections between ATC categories that can lead to (A) pharmacokinetic drug-drug interactions and (B) pharmacodynamic drug-drug interactions as described in this study.
Jcm 11 07172 g004
Jcm 11 07172 g005 550
Figure 5. Differences in hospitalization days for COVID-19 patients due to comorbidities, age, polypharmacy, DDIs, and CRP values. Statistically significant differences (* p < 0.05) are noted with horizontal brackets.
Figure 5. Differences in hospitalization days for COVID-19 patients due to comorbidities, age, polypharmacy, DDIs, and CRP values. Statistically significant differences (* p < 0.05) are noted with horizontal brackets.
Jcm 11 07172 g005
Table
Table 1. STROBE information for the study regarding methods and results.
Table 1. STROBE information for the study regarding methods and results.
Methods
Study designObservational, retrospective, and descriptive study of DDIs in patients admitted with COVID-19
SettingCOVID-19 ward, University Hospital Heraklion, Crete, Greece
ParticipantsPatients requiring inpatient treatment for COVID-19
VariablesRecord of demographic characteristics; clinical values; comorbidities; medication regimens; number of DDIs; clinical significance; hospitalization days
Data sources/
measurement		DDIs are based on literature searches and relative databases (Medscape, drugs.com, accessed on 1 April–30 July 2022)
Study sizeTarget population: patients admitted with COVID-19
Study population: signed informed consent form
BiasDiligence in informing the purpose and objectives of the study
Diligence in recording the medication regimens in the correct time periods
Recording demographics and medication regimens
Analysis of data regarding the significance
Results
ParticipantsThe informed consent form was signed by 125 participants (76 males/49 females)
Descriptive dataAverage comorbidities: 4.0
Average hospitalization days: 8.6 (median 7)
Admittance: laboratory confirmation for SARS-CoV-2
Vaccination status: 52% complete, 15% partial, and 23% none
Mortality: 13%
Outcome dataComorbidities: Cardiovascular disorders (58.4%) and diabetes (types I and II) (29.6%)
226 unique DDIs
PK-DDIs: 32.0% and PD-DDIs: 68.0%
Main resultsPatients with at least 1 potential DDI: 67.2% (admission), 92.8% (hospitalization), and 60% (discharge)
Clinically significant DDIs: 40.3% (admission), 21% (hospitalization), and 40.7% (discharge)
Patients with comorbidities had an increased number of DDIs (p < 0.05, 95% CI)
DDIs were more prevalent for patients in a polypharmacy state (p < 0.05, 95% CI)
Exponential correlation between DDIs and number of drugs
Clinically significant DDIs were observed in patients that also had prolonged hospitalization (p < 0.05, 95% CI)
COVID-19: coronavirus disease; DDIs: drug-drug interactions; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; PK: pharmacokinetic; PD: pharmacodynamic.
Table
Table 2. Demographic characteristics of patients enrolled in the study.
Table 2. Demographic characteristics of patients enrolled in the study.
DemographicsMean (±Standard Deviation) Min/Max
Age (y)72.5 (±14.7)33/97
Height (m)1.7 (±0.2)1.2/1.9
Weight (kg)81.3 (±19.2)48.0/130.0
Body Mass Index (BMI, kg/m2)33.1 (±9.1)22.2/50.0
Comorbidities4 (±3)0/12
Vaccination5% (3 doses); 14.4% (2 doses); 81.4% (1 or no dose)
Duration of hospitalization (d)8.6 (±4.7) (median = 7)2/74
Mortality 13% (13% fully; 1% partially and 20% unvaccinated)
Polypharmacy (≥5 drugs)Admission = 55.2%; Hospitalization = 82.0%; Discharge = 55.8%
Residence & Social Habits
Urban65 (52%)
Suburban9 (7%)
Semi-urban14 (11%)
Rural35 (28%)
Smoking38 (30%)
Table
Table 3. Pharmacological mechanisms of the recorded DDIs and their frequency (N).
Table 3. Pharmacological mechanisms of the recorded DDIs and their frequency (N).
Mechanisms of PK-DDIsN
Inhibition of CYP-mediated metabolism39
Reduced bioavailability due to pH-dependent solubility23
Reduced metabolism (non-CYP) 21
Dual inhibition of CYP metabolism, P-gp, or other proteins transport13
Increased serum urate and Ct of metabolite (oxypurinol)11
Inhibition of P-gp-mediated transport10
Induction of CYP-mediated metabolism10
Modulation of GI absorption4
Inhibition of influx-mediated transport (e.g., OAT1B1 or OCT2)3
Renal tubular clearance2
Protein binding competition2
Dual induction of CYP-mediated metabolism and P-gp transport2
Restore suppressed CYP expression caused by inflammation1
Decrease tubular secretion1
Mechanisms of PD-DDIs
Modulation of anticoagulation action and altered INR-monitor183
QT prolongation63
Risk for hyperkalemia25
Risk of tendon rupture24
Risk for hypoglycemia18
GI side effects16
Deterioration in renal function (elderly)11
PD antagonism-acute bronchospasm11
PD synergism, sedation, and respiratory depression9
PD antagonism-altered antihypertensive response7
Risk for hypokalemia7
Risk for hyperglycemia6
Reduce renal function and antihypertensive effect of ACE inhibitors4
Risk for serotonin syndrome4
PD synergism-hypotensive effects4
Risk for hyponatremia3
Additive anticholinergic effects3
PD-antagonism decreased effect of levodopa2
Hypotension with hyperglycemia2
PD-synergism cardiovascular side effects2
Quinolone administration may result in hyper- or hypoglycemia2
Risk for nephrotoxicity and/or ototoxicity.1
PD-antagonism of Ca2+ with Ca2+ channel blockers1
PD-synergism and excessive parasympatholytic effects1
PD-synergism increased risk for serious infection1
PK: pharmacokinetic; PD: pharmacodynamic; DDI: drug-drug interactions; CYP: cytochrome P450; OCT: organic cation transporter; GI: gastrointestinal tract; OATP1B1: organic anion transporter 1B1; QT: interval between the heart’s contraction and relaxation; ACE: angiotensin-converting enzyme.
Table
Table 4. Examples of drug pairs that can lead to DDIs as recorded in this study (bold are marked drugs used in COVID-19 medication protocols). (Abbreviations: ATC: anatomical therapeutic classification index, SUA: Serious-Use alternative, Monitor: use with caution-monitor, Moderate: moderate-minor, N: number of cases).
Table 4. Examples of drug pairs that can lead to DDIs as recorded in this study (bold are marked drugs used in COVID-19 medication protocols). (Abbreviations: ATC: anatomical therapeutic classification index, SUA: Serious-Use alternative, Monitor: use with caution-monitor, Moderate: moderate-minor, N: number of cases).
Drug ADrug BATCPharmacological OutcomeSignificanceN
AcenocoumarolMethylprednisoloneB01H02PD-INR-monitorMonitor3
RemdesivirJ05Monitor3
CeftriaxoneJ01SUA2
RosuvastatinA02Moderate2
EsomeprazoleC10PK-CYP inhibitionModerate3
AllopurinolFurosemideM04C03PK-Ct metaboliteMonitor11
AmiodaroneMetforminC01A10PK-renal clearanceModerate2
AspirinValsartan, TelmisartanN02C09PD-Renal function (elderly)Moderate7
RamiprilModerate3
AzithromycinMirtazapineJ01N06PD-QT prolongationMonitor2
CarvedilolDabigatranC07B01PK-P-gp inhibitionMonitor2
ClopidogrelEsomeprazole,
Omeprazole		B01A02PK-CYP inhibitionSUA10
DexamethasoneLevofloxacin, CiprofloxacinH02J01PD-Risk of tendon ruptureModerate16
DigoxinEsomeprazoleC01A02PK-P-gp inhibitionMonitor2
AzithromycinC01J01Monitor2
DiltiazemRivaroxabanC08B01PK-CYP, P-gp inhibitionMonitor2
EnoxaparinDabigatranB01B01PD-INR-monitorSUA2
Dexamethasone,
Methylprednisolone		H02Moderate91
BudesonideR03Moderate28
Azithromycin
Piperacilin
Ceftaroline		J01Moderate21
Moderate12
Moderate6
CitalopramC09Moderate4
Irbesartan, TelmisartanC09PD-hyperkalemiaModerate6
RamiprinN06Moderate5
EscitalopramEsomeprazoleN06A02PK-CYP inhibitionMonitor7
LeuprolideL02QT prolongationSUA3
GliclazideFurosemideA10C03PD-hyperglycemiaModerate2
AspirinN02PD-hypoglycemiaModerate2
HaloperidolQuetiapineN05N05PD-QT prolongationMonitor3
IndacaterolFormoterolR03C07PD-acute bronchospasmModerate2
InsulinLevofloxacinA10J01PD-blood glucoseMonitor2
IpratropiumQuetiapineR03N05PD-hypoglycemiaMonitor7
MethylprednisoloneLevofloxacinH02J01PD-risk of tendon ruptureModerate5
QuetiapineCiprofloxacin,
Levofloxacin		N05J01PD-QT prolongationMonitor5
SertralineN06Monitor2
RisperidoneN05Monitor2
RamiprilMetforminC09A10PD-hypoglycemiaModerate3
SalbutamolLevofloxacinR03J01PD-QT prolongationMonitor6
QuetiapineN05Monitor3
Escitalopram
Fluoxetine		N06Monitor2
Monitor2
BisoprololC07PD-acute bronchospasmModerate3
SpironlactoneKClC03A12PD-hyperkalemiaMonitor2
PK: pharmacokinetic; PD: pharmacodynamic; DDI: drug-drug interactions; CYP: cytochrome P450; Ct: plasma concentration, QT: interval between the heart’s contraction and relaxation.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Spanakis, M.; Ioannou, P.; Tzalis, S.; Papakosta, V.; Patelarou, E.; Tzanakis, N.; Patelarou, A.; Kofteridis, D.P. Drug-Drug Interactions among Patients Hospitalized with COVID-19 in Greece. J. Clin. Med. 2022, 11, 7172. https://doi.org/10.3390/jcm11237172

AMA Style

Spanakis M, Ioannou P, Tzalis S, Papakosta V, Patelarou E, Tzanakis N, Patelarou A, Kofteridis DP. Drug-Drug Interactions among Patients Hospitalized with COVID-19 in Greece. Journal of Clinical Medicine. 2022; 11(23):7172. https://doi.org/10.3390/jcm11237172

Chicago/Turabian Style

Spanakis, Marios, Petros Ioannou, Sotiris Tzalis, Vasiliki Papakosta, Evridiki Patelarou, Nikos Tzanakis, Athina Patelarou, and Diamantis P. Kofteridis. 2022. "Drug-Drug Interactions among Patients Hospitalized with COVID-19 in Greece" Journal of Clinical Medicine 11, no. 23: 7172. https://doi.org/10.3390/jcm11237172

APA Style

Spanakis, M., Ioannou, P., Tzalis, S., Papakosta, V., Patelarou, E., Tzanakis, N., Patelarou, A., & Kofteridis, D. P. (2022). Drug-Drug Interactions among Patients Hospitalized with COVID-19 in Greece. Journal of Clinical Medicine, 11(23), 7172. https://doi.org/10.3390/jcm11237172

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop